Company Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester.
IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | May 23, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 124 |
| CEO | Yujiro Hata |
Contact Details
Address: 7000 Shoreline Court, Suite 350 South San Francisco, California 94080 United States | |
| Phone | 650 443 6209 |
| Website | ideayabio.com |
Stock Details
| Ticker Symbol | IDYA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001676725 |
| CUSIP Number | 45166A102 |
| ISIN Number | US45166A1025 |
| Employer ID | 47-4268251 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yujiro S. Hata | President, Chief Executive Officer and Director |
| Andres Ruiz Briseno CPA | Principal Accounting Officer, Senior Vice President and Head of Finance and Investor Relations |
| Dr. Michael A. White Ph.D. | Chief Scientific Officer |
| Dr. Darrin M. Beaupre M.D., Ph.D. | Chief Medical Officer |
| Dr. Paul A. Barsanti Ph.D. | Chief Technology Officer |
| Douglas B. Snyder | Senior Vice President and General Counsel |
| Francine Zelaya | Vice President and Head of Human Resources |
| Mick O'Quigley | Chief of Staff and Clinical Development |
| Daniel A. Simon | Chief Business Officer |
| Stuart Dorman | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 8-K | Current Report |
| Oct 25, 2024 | 8-K | Current Report |
| Oct 4, 2024 | 8-K | Current Report |
| Sep 23, 2024 | 8-K | Current Report |
| Aug 26, 2024 | 144 | Filing |